Want to see AVR full AI Analyst Report?
Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.50
▼(-7.75% Downside)
Action:Reiterated
Date:08/03/26
The score is primarily held down by very weak financial performance—shrinking revenue, large ongoing losses, and heavy cash burn that elevates funding risk. Technicals are also a headwind with the stock trading below key short-term averages, though longer-term averages provide some support. Valuation is difficult to support with a negative P/E and no dividend yield, while corporate events are only modestly positive after a compliance-related trading halt was addressed.
Positive Factors
Focused aortic valve product strategy
A clear, specialized focus on transcatheter and surgical aortic valve replacement targets a durable, high‑value segment of structural heart disease. Persistent demand for valve therapies supports long‑term addressable market potential if clinical and regulatory progress continues.
Negative Factors
Severe and persistent cash burn
Very large negative operating and free cash flows are structurally material: continued burn requires frequent external financing, constrains strategic choices, and elevates dilution and runway risk. Sustainable progress depends on closing the gap between spend and revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused aortic valve product strategy
A clear, specialized focus on transcatheter and surgical aortic valve replacement targets a durable, high‑value segment of structural heart disease. Persistent demand for valve therapies supports long‑term addressable market potential if clinical and regulatory progress continues.
Read all positive factors
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$763.16M
Dividend YieldN/A
Average Volume (3M)151.40K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth-25.74%
EPS Growth2.38%
CountryUS
Employees174
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-4.00
Shares Outstanding97,342,200
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside96.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$9.87M
Anteris Technologies Global Corp. Business Overview & Revenue Model
Company Description
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering i...
How the Company Makes Money
null...
Anteris Technologies Global Corp. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.85M | 1.91M | 2.70M | 2.73M | 3.20M | 5.83M |
| Gross Profit | 523.00K | -317.00K | 1.27M | 876.80K | 298.38K | 1.91M |
| EBITDA | -92.94M | -92.49M | -74.38M | -45.54M | -29.14M | -15.50M |
| Net Income | -95.30M | -94.14M | -76.29M | -46.02M | -30.56M | -17.17M |
Balance Sheet | ||||||
| Total Assets | 294.72M | 23.00M | 80.70M | 30.53M | 15.99M | 21.43M |
| Cash, Cash Equivalents and Short-Term Investments | 283.21M | 12.58M | 70.46M | 21.03M | 9.29M | 15.46M |
| Total Debt | 3.73M | 2.28M | 1.40M | 1.60M | 952.79K | 4.14M |
| Total Liabilities | 16.31M | 23.25M | 18.02M | 11.63M | 6.95M | 10.91M |
| Stockholders Equity | 278.44M | -93.00K | 62.76M | 19.30M | 9.03M | 10.52M |
Cash Flow | ||||||
| Free Cash Flow | -86.69M | -79.76M | -63.51M | -37.03M | -31.08M | -15.02M |
| Operating Cash Flow | -84.99M | -77.80M | -61.24M | -34.63M | -29.42M | -14.44M |
| Investing Cash Flow | -1.89M | -596.00K | -2.28M | -2.58M | -992.57K | -886.07K |
| Financing Cash Flow | 321.16M | 20.55M | 112.83M | 49.34M | 23.27M | 27.42M |
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. disclosed 67 risk factors in its most recent earnings report. Anteris Technologies Global Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anteris Technologies Global Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $258.02M | -71.54 | -2.70% | ― | -2.50% | 93.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $174.63M | -7.09 | -13.17% | ― | 3.39% | 19.78% | |
52 Neutral | $279.60M | -4.44 | -69.50% | ― | -1.66% | -12.59% | |
49 Neutral | $106.12M | -1.92 | -177.04% | ― | 15.99% | -8.91% | |
46 Neutral | $171.84M | -18.42 | -78.70% | ― | 18.22% | 59.78% | |
43 Neutral | $763.16M | -1.96 | -124.39% | ― | -25.74% | 2.38% |
* General Sector Average
AVR
Anteris Technologies Global Corp.
8.91
5.41
154.57%
ANIK
Anika Therapeutics
21.42
13.21
160.90%
APYX
Apyx Medical
4.05
1.82
81.61%
INGN
Inogen
6.05
-0.99
-14.06%
TMCI
Treace Medical Concepts
4.76
-1.63
-25.51%
RPID
Rapid Micro Biosystems
1.73
-1.53
-46.93%
Anteris Technologies Global Corp. Corporate Events
Delistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
Court Orders Enable Anteris Trading Halt to Lift
Positive
Aug 3, 2026
On August 3, 2026, Anteris Technologies Global Corp. obtained orders from the Federal Court of Australia rectifying an inadvertent administrative oversight involving the late lodgement of a cleansing notice for 44,068 CHESS Depositary Interests is...
Delistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
Anteris Technologies Requests ASX Trading Halt for Relief
Negative
Jul 31, 2026
On July 31, 2026, Anteris Technologies Global Corp. requested a trading halt in its securities on the Australian Securities Exchange under ASX Listing Rule 17.1, while confirming that trading on the Nasdaq Global Market would remain unaffected. Th...
Business Operations and StrategyPrivate Placements and Financing
Anteris Launches $250 Million At-The-Market Stock Program
Neutral
May 22, 2026
On May 22, 2026, Anteris Technologies Global Corp. entered into a sales agreement with TD Securities (USA) LLC, under which it may issue and sell up to $250 million of its common stock through an at-the-market equity offering on Nasdaq and the ASX...
Executive/Board Changes
Anteris Technologies Adds Experienced Financial Leaders to Board
Positive
May 13, 2026
On May 11, 2026 in the U.S. (May 12, 2026 in Australia), Anteris Technologies Global Corp. appointed Susan Knight and returning director Stephen Denaro to its Board of Directors, assigning Knight as a Class I Director through the 2028 annual meeti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.